Charles River Laboratories Intl. Inc (CRL) Shares Sold by Stone Ridge Asset Management LLC

Stone Ridge Asset Management LLC lessened its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 19.6% during the 3rd quarter, Holdings Channel reports. The firm owned 5,740 shares of the medical research company’s stock after selling 1,400 shares during the quarter. Stone Ridge Asset Management LLC’s holdings in Charles River Laboratories Intl. were worth $772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund lifted its stake in Charles River Laboratories Intl. by 2.6% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 18,893 shares of the medical research company’s stock valued at $2,542,000 after acquiring an additional 484 shares during the period. MetLife Investment Advisors LLC lifted its stake in Charles River Laboratories Intl. by 1.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 30,113 shares of the medical research company’s stock valued at $3,380,000 after acquiring an additional 515 shares during the period. Investment House LLC lifted its stake in Charles River Laboratories Intl. by 0.7% during the 3rd quarter. Investment House LLC now owns 94,470 shares of the medical research company’s stock valued at $12,710,000 after acquiring an additional 615 shares during the period. Putnam Investments LLC lifted its stake in Charles River Laboratories Intl. by 1.0% during the 2nd quarter. Putnam Investments LLC now owns 70,913 shares of the medical research company’s stock valued at $7,961,000 after acquiring an additional 680 shares during the period. Finally, Sawgrass Asset Management LLC lifted its stake in Charles River Laboratories Intl. by 33.0% during the 2nd quarter. Sawgrass Asset Management LLC now owns 2,900 shares of the medical research company’s stock valued at $326,000 after acquiring an additional 720 shares during the period. 95.11% of the stock is currently owned by institutional investors.

CRL opened at $130.88 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.55 and a debt-to-equity ratio of 1.32. Charles River Laboratories Intl. Inc has a 1 year low of $96.70 and a 1 year high of $138.89. The firm has a market capitalization of $6.29 billion, a P/E ratio of 24.83, a PEG ratio of 1.84 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last posted its earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The firm had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. During the same period in the previous year, the business posted $1.30 EPS. The business’s revenue was up 26.1% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories Intl. Inc will post 5.92 earnings per share for the current fiscal year.

CRL has been the subject of several research reports. SunTrust Banks lifted their price objective on shares of Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Jefferies Financial Group lifted their price objective on shares of Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Barclays lifted their price objective on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, August 9th. Credit Suisse Group decreased their price objective on shares of Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating for the company in a research note on Tuesday, August 21st. Finally, Raymond James upgraded shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price objective for the company in a research note on Thursday, August 23rd. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $130.56.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,866 shares of the company’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $134.49, for a total transaction of $250,958.34. Following the completion of the transaction, the insider now directly owns 12,341 shares in the company, valued at $1,659,741.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David P. Johst sold 23,356 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the transaction, the insider now owns 219,849 shares of the company’s stock, valued at $29,899,464. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,288 shares of company stock valued at $3,930,176. Company insiders own 2.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/11/19/charles-river-laboratories-intl-inc-crl-shares-sold-by-stone-ridge-asset-management-llc.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Growth Stocks

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply